[HTML][HTML] Challenges of blood transfusions in β-thalassemia
Patients with β-thalassemia major (BTM) require regular blood transfusions, supported by
appropriate iron chelation therapy (ICT), throughout their life. β-thalassemia is a global …
appropriate iron chelation therapy (ICT), throughout their life. β-thalassemia is a global …
The development and consequences of red blood cell alloimmunization
CM Arthur, SR Stowell - Annual Review of Pathology …, 2023 - annualreviews.org
While red blood cell (RBC) transfusion is the most common medical intervention in
hospitalized patients, as with any therapeutic, it is not without risk. Allogeneic RBC exposure …
hospitalized patients, as with any therapeutic, it is not without risk. Allogeneic RBC exposure …
[HTML][HTML] Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international …
E Angelucci, S Matthes-Martin, D Baronciani… - …, 2014 - ncbi.nlm.nih.gov
Thalassemia major and sickle cell disease are the two most widely disseminated hereditary
hemoglobinopathies in the world. The outlook for affected individuals has improved in recent …
hemoglobinopathies in the world. The outlook for affected individuals has improved in recent …
Clinically significant red blood cell antibodies in chronically transfused patients: a survey of Chinese thalassemia major patients and literature review
CK Cheng, CK Lee, CK Lin - Transfusion, 2012 - Wiley Online Library
BACKGROUND: Red blood cell (RBC) alloimmunization is reported to occur at an incidence
of 5.2% to 23.5% among patients with thalassemia requiring chronic transfusion. With very …
of 5.2% to 23.5% among patients with thalassemia requiring chronic transfusion. With very …
Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease
RM Fasano, GS Booth, M Miles, L Du… - British journal of …, 2015 - Wiley Online Library
Sickle cell disease (SCD) patients are at increased risk of red blood cell (RBC)
alloimmunization. Recipient inflammatory state at time of transfusion has been shown to …
alloimmunization. Recipient inflammatory state at time of transfusion has been shown to …
[HTML][HTML] A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
Beta-thalassaemia causes defective haemoglobin synthesis leading to ineffective
erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood …
erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood …
Systematic literature review of the burden of disease and treatment for transfusion-dependent β-thalassemia
M Betts, PA Flight, LC Paramore, L Tian… - Clinical Therapeutics, 2020 - Elsevier
Purpose β-Thalassemia is an inherited blood disorder characterized by reduced or no
production of adult hemoglobin. Systematic identification of the burden of β-thalassemia with …
production of adult hemoglobin. Systematic identification of the burden of β-thalassemia with …
Challenges of alloimmunization in patients with haemoglobinopathies
Red blood cell (RBC) transfusions can be life‐sustaining in chronic inherited anaemias,
such as thalassaemia, and the indications for blood transfusions in patients with sickle cell …
such as thalassaemia, and the indications for blood transfusions in patients with sickle cell …
Thalassemias.
A Martin, AA Thompson - Pediatric Clinics of North America, 2013 - europepmc.org
The thalassemia syndromes are hemoglobin disorders that result from significantly reduced
or absent synthesis of either the α-or β-globin chains. The result is a chronic hemolytic …
or absent synthesis of either the α-or β-globin chains. The result is a chronic hemolytic …
Transfusion complications in thalassemia patients: a report from the C enters for D isease C ontrol and P revention (CME)
E Vichinsky, L Neumayr, S Trimble, PJ Giardina… - …, 2014 - Wiley Online Library
Background Transfusions are the primary therapy for thalassemia but have significant
cumulative risks. In 2004, the C enters for D isease C ontrol and P revention (CDC) …
cumulative risks. In 2004, the C enters for D isease C ontrol and P revention (CDC) …